Developer docs
API playgroundTry for free, no card

Search company profiles

Bio-Sourcing

Full company profile

uuid0002l8y

Namestring
Bio-Sourcing
Legal namestring
Société Anonyme BIO-SOURCING
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Bio-Sourcing is a Belgian biotechnology company founded in 2014 and headquartered in Liège that has developed the BioMilk platform—a proprietary system using transgenic goats as 'natural bioreactors' to produce fully human monoclonal antibodies and other biopharmaceuticals in goat milk. The platform combines CRISPR-Cas9 gene editing, nuclear transfer, and in vitro fertilization to engineer goats whose milk contains therapeutic proteins at industrial scale; downstream purification yields pharmaceutical-grade products branded as 'BioBodies,' positioned as biosimilars and biobetters with claims of improved glycosylation profiles and materially lower capital and operating costs than mammalian cell-culture bioreactor facilities (traditional plants costing $250–500M in capex).

The company addresses three customer segments: large pharmaceutical companies seeking to lower the cost of monoclonal antibody production, governments and emerging-market countries lacking domestic biopharmaceutical manufacturing capacity, and biotech partners developing oral biologics delivery systems. Bio-Sourcing operates a co-development and co-ownership business model, generating early income through development agreements and long-term revenue through licensing royalties rather than direct product sales. Recent strategic moves include a €1.3 million EUREKA Eurostars-funded joint project with Zerion Pharma (January 2026) to develop an oral formulation of trastuzumab targeting the $4.1 billion global trastuzumab market by 2030, and a strategic alliance with The Tiny Cargo Company (March 2026) to co-develop orally delivered monoclonal antibodies using goat milk-derived exosomes—a category in which no FDA- or EMA-approved products currently exist.

Bio-Sourcing is led by Founder and CEO Dr. Bertrand Mérot, a geneticist and former executive at LFB Biotechnology, GTC Biotherapeutics, and Limagrain Group, supported by a team of 15 scientists including a CSO with dual PhDs from the University of Liège and Oxford. In September 2024 the company secured €12.5 million from the EIC Accelerator (€2.5 million grant plus €10 million equity) to scale goat herds, build an industrial milk processing plant, and fund clinical trials. The company remains at pre-clinical to early-clinical stage with no approved products and Phase I trials for oral trastuzumab targeted around 2030.

Short descriptiontext

Bio-Sourcing is a Belgian biotech company developing the BioMilk platform, which uses transgenic goats to produce monoclonal antibodies and other biopharmaceuticals in milk for pharmaceutical companies, emerging-market governments, and biotech partners via co-development and licensing agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLiège, Belgium
HQ citystring
Liège
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody production, transgenic biotherapeutics, biosimilar development, recombinant protein expression, biopharmaceutical manufacturing
NAICS code1 code
  • Animal Food Manufacturing3111
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Co-development and Licensing
TypeLicensing Royalties
Description

Business model based on co-development and co-ownership of results with pharmaceutical partners, generating early income and long-term royalty revenues from biosimilar and biobetter products developed using the BioMilk platform.

bio-sourcing.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BioMilk
Description

Proprietary technological platform to express proteins of interest in the milk of dedicated animals using transgenic goats as natural bioreactors.

bio-sourcing.com
Core offering1 text field

Bio-Sourcing develops and operates the proprietary BioMilk™ platform, which produces monoclonal antibodies and other biopharmaceuticals in the milk of transgenic goats. The company co-develops biosimilars and biobetters (including adalimumab and trastuzumab) with pharmaceutical partners, governments, and biotech firms, generating early development income and long-term royalty revenues.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Production volumes achievable at drastically lower cost for volumes larger than a ton compared to traditional steel bioreactors
+2 more records
Product overview1 text field

Bio-Sourcing offers a single unified technology platform called BioMilk™ for producing biopharmaceuticals. The platform uses transgenic goats as natural bioreactors to express therapeutic proteins (particularly monoclonal antibodies) in milk. The company produces improved biopharmaceuticals called BioBodies, which feature better glycosylation profiles compared to traditional production methods. The platform enables drastic reduction of capital requirements and production costs, particularly for volumes exceeding one ton, while meeting sustainable development goals.

Product and service2 records
1BioMilk™ Platform
CategoryBioproduction platform / Biopharmaceutical manufacturing technology
Description

Proprietary biopharmaceutical production platform that expresses proteins of interest — including fully human monoclonal antibodies — in the milk of transgenic goats created via gene therapy and in vitro fertilization, then purifies them to pharmaceutical grade. Offered to pharmaceutical companies, governments and biotech partners via co-development and licensing arrangements.

2BioBodies (biosimilars and biobetters produced on the BioMilk platform)
CategoryBiosimilars and biobetters (monoclonal antibodies)
Description

Improved biopharmaceutical products (biosimilars and biobetters) such as adalimumab and trastuzumab, manufactured via the BioMilk platform with enhanced glycosylation profiles. Co-developed with pharmaceutical partners under co-ownership and long-term royalty arrangements.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Strategic collaboration to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes as delivery vehicles. The partnership combines Bio-Sourcing's scalable goat-milk production platform for mAbs and milk EVs with Tiny Cargo's cGMP-ready industrial exosome purification and loading technology. The goal is to create patient-friendly, shelf-stable biologics that eliminate the need for injections and reduce hospital visits. No FDA or EMA-approved oral mAbs currently exist, making this alliance a potential leader in addressing the 'needle barrier'.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Joint project awarded €1.3 million EUREKA Eurostars funding to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project leverages Bio-Sourcing's BioMilk platform and Zerion's Dispersome technology to create an orally deliverable trastuzumab biobetter, with preclinical validation and Phase I studies targeted for around 2030. The global trastuzumab market is estimated at $4.1 billion by 2030.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch biotech using transgenic rabbits to produce recombinant C1 esterase inhibitor (Ruconest) for hereditary angioedema. The most direct commercial-stage comparable to Bio-Sourcing's transgenic animal-produced therapeutic platform.

TypeDirect peer
Description

US biotech using transgenic cattle to produce fully human polyclonal antibodies for infectious disease and oncology. Same core paradigm of transgenic animals as natural bioreactors at industrial scale.

TypeDirect peer
Description

French plasma/biotech group that acquired GTC Biotherapeutics and markets ATryn, the only FDA-approved transgenic animal-produced therapeutic (made in goat milk). Bio-Sourcing's CEO Dr. Mérot was previously at GTC, making LFB/GTC a direct platform precedent.

TypeBroad incumbent
Description

Korean biosimilars joint venture with approved biosimilars of adalimumab (Hadlima), trastuzumab (Ontruzant), and others. Direct end-product competitor to Bio-Sourcing's biosimilar/biobetter pipeline.

TypeBroad incumbent
Description

Korean biosimilars leader with approved infliximab (Remsima), rituximab (Truxima), and trastuzumab (Herzuma). Operates in the same target market as Bio-Sourcing's biosimilar ambitions.

TypeBroad incumbent
Description

Indian biosimilars leader with multiple approved products (including adalimumab and trastuzumab biosimilars) targeting emerging and developed markets. Competes with Bio-Sourcing for the same biosimilar mAb market.

TypeBroad incumbent
Description

Sanofi acquired Ablynx in 2018 for its camelid nanobody platform, which uses transgenic animals (llamas) to produce therapeutic single-domain antibodies. Closest large-pharma example of the transgenic animal-derived antibody model.

TypeRegional player
Description

Belgian biotech developing innovative antibody fragment therapeutics (Vyvgart approved for myasthenia gravis). Geographic peer in Belgium's biotech cluster and category peer in differentiated antibody therapeutics.

TypeBroad incumbent
Description

Originator of Humira (adalimumab) and now biosimilar competitor with Amjevita. Established incumbent comparator whose commercial scale, pricing leverage, and market access set the bar Bio-Sourcing must undercut.

TypeBroad incumbent
Description

Swiss pharma and originator of Herceptin (trastuzumab) via Genentech. The dominant incumbent whose $4.1B-by-2030 trastuzumab market Bio-Sourcing's biosimilar/biobetter strategy explicitly aims to address.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio-Sourcing

Biopharmaceutical Manufacturingbio-sourcing.com

Bio-Sourcing is a Belgian biotech company developing the BioMilk platform, which uses transgenic goats to produce monoclonal antibodies and other biopharmaceuticals in milk for pharmaceutical companies, emerging-market governments, and biotech partners via co-development and licensing agreements.

What Bio-Sourcing does

Bio-Sourcing is a Belgian biotechnology company founded in 2014 and headquartered in Liège that has developed the BioMilk platform—a proprietary system using transgenic goats as 'natural bioreactors' to produce fully human monoclonal antibodies and other biopharmaceuticals in goat milk. The platform combines CRISPR-Cas9 gene editing, nuclear transfer, and in vitro fertilization to engineer goats whose milk contains therapeutic proteins at industrial scale; downstream purification yields pharmaceutical-grade products branded as 'BioBodies,' positioned as biosimilars and biobetters with claims of improved glycosylation profiles and materially lower capital and operating costs than mammalian cell-culture bioreactor facilities (traditional plants costing $250–500M in capex).

The company addresses three customer segments: large pharmaceutical companies seeking to lower the cost of monoclonal antibody production, governments and emerging-market countries lacking domestic biopharmaceutical manufacturing capacity, and biotech partners developing oral biologics delivery systems. Bio-Sourcing operates a co-development and co-ownership business model, generating early income through development agreements and long-term revenue through licensing royalties rather than direct product sales. Recent strategic moves include a €1.3 million EUREKA Eurostars-funded joint project with Zerion Pharma (January 2026) to develop an oral formulation of trastuzumab targeting the $4.1 billion global trastuzumab market by 2030, and a strategic alliance with The Tiny Cargo Company (March 2026) to co-develop orally delivered monoclonal antibodies using goat milk-derived exosomes—a category in which no FDA- or EMA-approved products currently exist.

Bio-Sourcing is led by Founder and CEO Dr. Bertrand Mérot, a geneticist and former executive at LFB Biotechnology, GTC Biotherapeutics, and Limagrain Group, supported by a team of 15 scientists including a CSO with dual PhDs from the University of Liège and Oxford. In September 2024 the company secured €12.5 million from the EIC Accelerator (€2.5 million grant plus €10 million equity) to scale goat herds, build an industrial milk processing plant, and fund clinical trials. The company remains at pre-clinical to early-clinical stage with no approved products and Phase I trials for oral trastuzumab targeted around 2030.

Bio-Sourcing firmographics

Firmographics
Name
Bio-Sourcing
Legal name
Société Anonyme BIO-SOURCING
Website
https://bio-sourcing.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Bio-Sourcing is a Belgian biotech company developing the BioMilk platform, which uses transgenic goats to produce monoclonal antibodies and other biopharmaceuticals in milk for pharmaceutical companies, emerging-market governments, and biotech partners via co-development and licensing agreements.
Ownership category
akta.pro rank

Where Bio-Sourcing is headquartered

Location

Headquarters

HQ city
Liège
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Bio-Sourcing business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Co-development and Licensing: Business model based on co-development and co-ownership of results with pharmaceutical partners, generating early income and long-term royalty revenues from biosimilar and biobetter products developed using the BioMilk platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Bio-Sourcing product offering

Product offering

Core offering

Bio-Sourcing develops and operates the proprietary BioMilk™ platform, which produces monoclonal antibodies and other biopharmaceuticals in the milk of transgenic goats. The company co-develops biosimilars and biobetters (including adalimumab and trastuzumab) with pharmaceutical partners, governments, and biotech firms, generating early development income and long-term royalty revenues.

Product overview

Bio-Sourcing offers a single unified technology platform called BioMilk™ for producing biopharmaceuticals. The platform uses transgenic goats as natural bioreactors to express therapeutic proteins (particularly monoclonal antibodies) in milk. The company produces improved biopharmaceuticals called BioBodies, which feature better glycosylation profiles compared to traditional production methods. The platform enables drastic reduction of capital requirements and production costs, particularly for volumes exceeding one ton, while meeting sustainable development goals.

Differentiator

Problem solved

Functional benefit

Brands

  • BioMilk: Proprietary technological platform to express proteins of interest in the milk of dedicated animals using transgenic goats as natural bioreactors.

Products and services

  • BioMilk™ Platform Proprietary biopharmaceutical production platform that expresses proteins of interest — including fully human monoclonal antibodies — in the milk of transgenic goats created via gene therapy and in vitro fertilization, then purifies them to pharmaceutical grade. Offered to pharmaceutical companies, governments and biotech partners via co-development and licensing arrangements.
  • BioBodies (biosimilars and biobetters produced on the BioMilk platform) Improved biopharmaceutical products (biosimilars and biobetters) such as adalimumab and trastuzumab, manufactured via the BioMilk platform with enhanced glycosylation profiles. Co-developed with pharmaceutical partners under co-ownership and long-term royalty arrangements.

Quantifiable outcome

  • Production volumes achievable at drastically lower cost for volumes larger than a ton compared to traditional steel bioreactors
  • +2 more outcomes

Companies that use Bio-Sourcing

Customer profile

Segments3 records

Ideal customer profiles3 records

Bio-Sourcing technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bio-Sourcing partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • The Tiny Cargo CompanycoreStrategic or Co-development Partner · 18 March 2026Strategic collaboration to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes as delivery vehicles. The partnership combines Bio-Sourcing's scalable goat-milk production platform for mAbs and milk EVs with Tiny Cargo's cGMP-ready industrial exosome purification and loading technology. The goal is to create patient-friendly, shelf-stable biologics that eliminate the need for injections and reduce hospital visits. No FDA or EMA-approved oral mAbs currently exist, making this alliance a potential leader in addressing the 'needle barrier'.
  • Zerion Pharma A/ScoreStrategic or Co-development Partner · 12 January 2026Joint project awarded €1.3 million EUREKA Eurostars funding to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project leverages Bio-Sourcing's BioMilk platform and Zerion's Dispersome technology to create an orally deliverable trastuzumab biobetter, with preclinical validation and Phase I studies targeted for around 2030. The global trastuzumab market is estimated at $4.1 billion by 2030.

Scale indicators3 records

Recent moves3 records

Expansion highlights5 records

Bio-Sourcing competitors and assessment

Company assessment

Direct peers

  • Pharming Group: Dutch biotech using transgenic rabbits to produce recombinant C1 esterase inhibitor (Ruconest) for hereditary angioedema. The most direct commercial-stage comparable to Bio-Sourcing's transgenic animal-produced therapeutic platform.
  • SAB Biotherapeutics: US biotech using transgenic cattle to produce fully human polyclonal antibodies for infectious disease and oncology. Same core paradigm of transgenic animals as natural bioreactors at industrial scale.
  • LFB Group: French plasma/biotech group that acquired GTC Biotherapeutics and markets ATryn, the only FDA-approved transgenic animal-produced therapeutic (made in goat milk). Bio-Sourcing's CEO Dr. Mérot was previously at GTC, making LFB/GTC a direct platform precedent.

Broad incumbents

  • Samsung Bioepis: Korean biosimilars joint venture with approved biosimilars of adalimumab (Hadlima), trastuzumab (Ontruzant), and others. Direct end-product competitor to Bio-Sourcing's biosimilar/biobetter pipeline.
  • Celltrion: Korean biosimilars leader with approved infliximab (Remsima), rituximab (Truxima), and trastuzumab (Herzuma). Operates in the same target market as Bio-Sourcing's biosimilar ambitions.
  • Biocon Biologics: Indian biosimilars leader with multiple approved products (including adalimumab and trastuzumab biosimilars) targeting emerging and developed markets. Competes with Bio-Sourcing for the same biosimilar mAb market.
  • Sanofi (Ablynx): Sanofi acquired Ablynx in 2018 for its camelid nanobody platform, which uses transgenic animals (llamas) to produce therapeutic single-domain antibodies. Closest large-pharma example of the transgenic animal-derived antibody model.
  • Amgen: Originator of Humira (adalimumab) and now biosimilar competitor with Amjevita. Established incumbent comparator whose commercial scale, pricing leverage, and market access set the bar Bio-Sourcing must undercut.
  • Roche: Swiss pharma and originator of Herceptin (trastuzumab) via Genentech. The dominant incumbent whose $4.1B-by-2030 trastuzumab market Bio-Sourcing's biosimilar/biobetter strategy explicitly aims to address.

Regional players

  • Argenx: Belgian biotech developing innovative antibody fragment therapeutics (Vyvgart approved for myasthenia gravis). Geographic peer in Belgium's biotech cluster and category peer in differentiated antibody therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Bio-Sourcing financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio-Sourcing leadership team

Management profile

Number of profiles

Profiles8 records

Bio-Sourcing funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio-Sourcing M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Sourcing

What does Bio-Sourcing do?

Bio-Sourcing develops and operates the proprietary BioMilk™ platform, which produces monoclonal antibodies and other biopharmaceuticals in the milk of transgenic goats. The company co-develops biosimilars and biobetters (including adalimumab and trastuzumab) with pharmaceutical partners, governments, and biotech firms, generating early development income and long-term royalty revenues.

Is Bio-Sourcing a public or private company?

Bio-Sourcing is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bio-Sourcing founded?

Bio-Sourcing was founded in 2014. It employs 11 to 50 people.

Where is Bio-Sourcing based?

Bio-Sourcing is headquartered in Liège, Belgium, in the Europe region.

How does Bio-Sourcing make money?

One revenue line is on record: co-development and Licensing.

Who are Bio-Sourcing's main competitors?

Direct peers on record are Pharming Group, SAB Biotherapeutics and LFB Group. Broad incumbents are Samsung Bioepis, Celltrion, Biocon Biologics, Sanofi (Ablynx), Amgen and Roche. Argenx is listed as a regional player.

Does Bio-Sourcing have an API?

No public API is recorded for Bio-Sourcing.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsBio-Sourcing and Tiny Cargo Partner on Orally Delivered mAbs Using Goat Milk ExosomesLiège-based Bio-Sourcing and Roanoke-based The Tiny Cargo Company have entered a strategic collaboration to co-develop orally delivered monoclonal antibody therapies using goat milk-derived extracellular vesicles and exosomes, combining Bio-Sourcing's BioMilk® transgenic goat milk production platform with Tiny Cargo's cGMP-ready industrial exosome extraction and loading technology. The partnership aims to create patient-friendly oral biologics, with two initial programs targeting oral formulations of adalimumab (Humira) for Crohn's disease and trastuzumab (Herceptin) for HER2+ breast cancer, with Clinical Trial Application submissions targeted for early 2027 and 2028 respectively. The companies highlight that there are currently no approved oral mAbs, representing an innovative gap their alliance intends to address, with Tiny Cargo having opened a $1.5 million cGMP-ready manufacturing facility in Roanoke, VA in February 2026.PharmiWeb.comTiny Cargo and Bio-Sourcing Partner to Develop First-of-Its-Kind Oral Monoclonal Antibody Platform Using Goat-Milk ExosomesThe Tiny Cargo Company and Bio-Sourcing SA announced a strategic partnership to develop an oral delivery platform for monoclonal antibodies using goat-milk-derived exosomes, combining Tiny Cargo's industrial-scale exosome isolation and loading capabilities with Bio-Sourcing's high-yield mAb production in goat milk. The collaboration aims to eliminate the need for injectable biologics by leveraging milk exosomes' natural ability to survive the gut environment and transport therapeutic molecules into the bloodstream. No FDA or EMA-approved oral mAbs currently exist, making this US-EU alliance a potential leader in addressing the 'needle barrier' that has historically limited biologics access.Onco'ZineEuropean Biotech Companies to Receive Funding to Develop an Orally Administered anti‑HER2 Antibody for Treatment of Breast CancerBelgium-based Bio-Sourcing and Danish Zerion Pharma have secured €1.3 million in EUREKA Eurostars funding to develop an oral biobetter formulation of trastuzumab (Herceptin) for treating HER2-positive breast cancer. The 36-month project will combine Bio-Sourcing's BioMilk platform with Zerion's Dispersome technology to overcome gastrointestinal barriers, with the aim of advancing to Phase I clinical studies around 2030. The global trastuzumab market is projected to reach USD 4.1 billion by 2030, and an oral formulation could improve patient adherence while reducing healthcare burden compared to current infusion-based treatments.ZerionPress ReleasesBio-Sourcing and Zerion Pharma have been awarded a €1.3 million EUREKA Eurostars grant to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project will leverage Bio-Sourcing's BioMilk platform and Zerion's Dispersome technology to create an orally deliverable version of the drug, with preclinical validation and Phase I studies targeted for around 2030. The global trastuzumab market is estimated at $4.1 billion by 2030, and an oral formulation could expand patient access while reducing reliance on infusion centers.BioSpaceBio-Sourcing and Zerion Pharma Join Forces to Develop First HER2 Oral Monoclonal Antibody Against Breast CancerBio-Sourcing and Zerion Pharma have been awarded a €1.3 million EUREKA Eurostars grant to develop an oral formulation of Trastuzumab for treating HER2-positive breast cancer, using Bio-Sourcing's BioMilk™ platform and Zerion's Dispersome® technology. The 36-month project will progress the formulation through preclinical validation with the aim of entering Phase I clinical studies around 2030. With the global trastuzumab market estimated at $4.1 billion by 2030, the companies seek to differentiate by offering an oral alternative to infusion-based therapy that could improve patient convenience and expand access to treatment.Business Wire BlogBio-Sourcing and Zerion Pharma Join Forces to Develop First HER2 Oral Monoclonal Antibody Against Breast CancerBio-Sourcing and Zerion Pharma A/S have been awarded EUREKA Eurostars funding for a joint project to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project will leverage Bio-Sourcing's BioMilk™ platform and Zerion's Dispersome® technology to create an orally deliverable trastuzumab biobetter, with the goal of entering Phase I clinical studies around 2030. The €1.3 million initiative targets a global trastuzumab market estimated at $4.1 billion by 2030, aiming to improve patient convenience and expand access to breast cancer treatment.Business Wire BlogBio-Sourcing Secures European Innovation Council (EIC) Accelerator Funding to Bridge the Biomanufacturing Gap and Make Biotherapeutics More Available and AffordableBio-Sourcing, a Belgian biotherapeutics company, secured €2.5M in grants and €10M in equity from the European Innovation Council Accelerator. The funding will enable the first biosimilar adalimumab to enter clinical trials by 2027, with revenues reinvested into further R&D. The company plans to expand its goat facility and industrial milk processing plant.FinSMEsBio-Sourcing Secures €12.5M in FundingBio-Sourcing secured €12.5 million in funding, comprising a €2.5 million grant from the European Innovation Council (EIC) Accelerator and €10 million in equity, to advance its BioMilk™ platform into clinical trials by 2027. This capital will support the development of its first biosimilar, adalimumab, while also financing the expansion of goat facilities and an industrial milk processing plant.Africa Newsroom / Press Releases Related to AfricaBio-Sourcing secures European Innovation Council (EIC) Accelerator funding to bridge the biomanufacturing gap and make biotherapeutics more available and affordableBio-Sourcing has secured a €2.5M grant and an additional €10M in equity funding from the European Innovation Council (EIC) Accelerator to develop its BioMilk platform, aiming to increase the accessibility of biotherapeutics like biosimilars. The funds will aid in clinical trials for their first biosimilar, adalimumab, and support infrastructure expansion, underscoring the significance of their innovative production methods. This initiative positions Europe to enhance its self-sufficiency in biopharmaceutical manufacturing, addressing global healthcare challenges.Tech.euBio-Sourcing secures €12.5M from EIC Accelerator for biotherapeutic productionBelgian biotech company Bio-Sourcing secured €12.5 million in funding from the European Innovation Council (EIC) Accelerator, comprising a €2.5 million grant and €10 million in equity. This capital will support clinical trials for its first biosimilar, adalimumab, by 2027 and facilitate the scaling of its proprietary BioMilk production platform. The investment aims to reduce manufacturing costs and enhance Europe's sovereignty in biopharmaceutical supply chains.